Variations on hormone replacement therapy: An answer to the 'one dose fits all' Women's Health Initiative study

Gynecological Endocrinology

Volumn 23, Issue 11, 2007, Pages 665-671

  Studd, John ^a  

^a London PMS and Menopause Centre   (United Kingdom)

Author keywords

Age; Depression; Estrogens; Osteoporosis; Premenstrual syndrome; Testosterone; WHI

Indexed keywords

CLONIDINE; ESTRADIOL; GESTAGEN; LEVONORGESTREL; MEDROXYPROGESTERONE; NORETHISTERONE; SEROTONIN UPTAKE INHIBITOR; TIBOLONE;

BREAST CANCER; CLIMACTERIUM; DEPRESSION; EARLY MENOPAUSE; GROUPS BY AGE; HEADACHE; HEART PALPITATION; HORMONE SUBSTITUTION; HOT FLUSH; HUMAN; HYSTERECTOMY; INSOMNIA; LOW DRUG DOSE; MENOPAUSAL SYNDROME; NIGHT SWEAT; OSTEOPOROSIS; OVARIECTOMY; POSTMENOPAUSE; PRIORITY JOURNAL; REVIEW; SALPINGOOOPHORECTOMY; SEXUAL DYSFUNCTION; SYMPTOM; TREATMENT INDICATION; VAGINAL DRYNESS; VASOMOTOR DISORDER; WOMEN'S HEALTH;

AGED; AGING; BONE DENSITY; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; MENOPAUSE; MENOPAUSE, PREMATURE; MIDDLE AGED; POSTMENOPAUSE; WOMEN'S HEALTH;

EID: 36248999477     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.1080/09513590701671878     Document Type: Review

References (45)

1. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, et al.; Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. J Am Med Assoc 2002;288:321-333.
2. Beral V. Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003;362:419-427.
3. Studd JW. 'Up to general practice to pick up the pieces' - what pieces? - a response to WHI and MWS. Maturitas 2003;46:95-96.
4. Harman SM, Naftolin F, Brinton EA, Judelson DR. Is the estrogen controversy over? Deconstructing the Women's Health Initiative study: a critical evaluation of the evidence. Ann N Y Acad Sci 2005;1052:43-56.
5. Clark JH. A critique of Women's Health Initiative studies (2002-2006). Nucl Recep Signal 2006;4:e023.
6. Whitehead M, Farmer R. The Million Women Study: a critique. Endocrine 2004;24:187-193.
7. Speroff L. The Million Women Study and breast cancer. Maturitas 2003;46:1-6.
8. Genazzani AR, Gambacciani M. The sound of an international anti-HRT herald. Maturitas 2003;46:105-106.
9. Conference report. 13th Annual Meeting of the North American Menopause Society October 2002. Chicago, Illinois.
10. RCP (Edin) Consensus conference on HRT Oct 2003.
11. Studd JW. Second thoughts on the Women's Health Initiative study: the effect of age on the safety of HRT. Climacteric 2004;7:412-414.
12. Manson JE, Hsia J, Johnson KC, Rossouw JE, Assaf AR, Lasser NL, Trevisan M, Black HR, Heckbert SR, Detrano R, Strickland OL, et al.; Women's Health Initiative Investigators. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003;349:523-534.
13. Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, Bonds D, Brunner R, Brzyski R, Caan B, et al.; The Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: The Women's Health Initiative randomized controlled trial. J Am Med Assoc 2004;291:1701-1712.
14. Nelson LM, Covington SN, Rebar RW. An update: spontaneous premature ovarian failure is not an early menopause. Fertil Steril 2005;83:1327-1332.
15. Khastgir G, Studd JW. Patients' outlook, experience and satisfaction with hysterectomy, bilateral oophorectomy and subsequent continuation of hormone replace therapy. Am J Obstet Gynecol 2000;183:1427-1433.
16. Campbell S, Whitehead M. Oestrogen therapy and the menopausal syndrome. Clin Obstet Gynaecol 1977;4:31-47.
17. Khastgir G, Studd J, Holland N, Alaghband-Zadeh J, Fox S, Chow J. Anabolic effect of estrogen replacement on bone in postmenopausal women with osteoporosis; histomorphometric evidence in a longitudinal study. J Clin Endocrinol Metab 2001;86:289-295.
18. Montgomery JC, Appleby L, Brincat M, Versi E, Tapp A, Fenwick PB, Studd JW. Effect of estrogen and testosterone implants on psychological disorders in the climacteric. Lancet 1987;1:297-299.
19. Watson NR, Savvas M, Studd JW, Garnett T, Barnet RJ. Treatment of severe pre-menstrual syndrome with oestradiol patches and cyclical oral norethisterone. Lancet 1989;ii:730-734.
20. Soares CN, Joffe H, Steiner M. Menopause and mood. Clin Obstet Gynecol 2004;47:576-591.
21. Schmidt PJ. Mood, depression and reproductive hormones in the menopausal transition. Am J Psychiatry 2006;163:133-137.
22. Davis SR. The use of testosterone after menopause. J Br Menopause Soc 2004;10:65-69.
23. Sturdee DW, Wade-Evans T, Paterson ME, Thom M, Studd JW. Relations between bleeding pattern, endometrial histology, and oestrogen treatment in menopausal woman. Br Med J 1987;1:1575-1577.
24. Magos AL, Brewster E, Singh R, O'Dowd T, Brincat M, Studd JW. The effects of norethisterone in postmenopausal women on oestrogen replacement therapy: a model for the premenstrual syndrome. Br J Obstet Gynaecol 1968;93:1290-1296.
25. Panay N, Studd JW. Progestogen intolerance and compliance with hormone replacement therapy in menopausal women. Hum Reprod Update 1997;3:159-171.
26. Hampton NR, Rees MC, Lowe DG, Rauamol I, Barlow D, Guillebaud J. Levonorgestrel intrauterine system (LNG-IUS) with conjugated oral equine estrogen: a successful regimen for HRT in perimenopausal women. Hum Reprod 2005;20:2653-2660.
27. Ettinger B, Ensrud KE, Wallace R, Johnson KC, Cummings SR, Yankov V, Vittinghoff E, Grady D. Effects of ultralow-dose transdermal estradiol on bone mineral density: a randomized clinical trial. Obstet Gynecol 2004;104:443-451.
28. Paterson ME, Wade-Evans T, Sturdee DW, Thom MH, Studd JW. Endometrial disease after treatment with oestrogens and progestogens in the climacteric. Br Med J 1980;280:822-824.
29. Brincat M, Moniz C, Studd J, Darby A, Magos A, Embury G, Versi E. Long term effects of the menopause and sex hormones on skin thickness. Br J Obstet Gynaecol 1985;92:256-259.
30. Oliver M, Boyd GS. Effect of bilateral ovariectomyon coronaryartery disease and serum-lipid levels. Lancet 1959;2:690-694.
31. Khastigir G, Studd JW, Fox SW, Jones J, Alaghband-Zadeh J, Chow J. A longitudinal study of the effect of subcutaneous estrogen replacement in bone in young women with Turner's syndrome. J Bone Miner Res 2003;18:925-932.
32. Sands R, Studd JW. Exogenous androgens in postmenopausal women. Am J Med 1995;98:76S-79S.
33. Studd J, Panay N. Hormones and depression in women. Climacteric 2004;7:338-346.
34. Stevenson J. Justification for the use of HRT in the long-term prevention of osteoporosis. Maturitas 2005;51:113-126.
35. Banks E, Beral V, Reeves G, Balkwill A, Barnes I; Million Women Study Collaborators. Fracture incidence in relation to the pattern of use of hormone therapy in postmenopausal women. J Am Med Assoc 2004;291:2212-2220.
36. Simon JA, Wehren LE, Ascott-Evans BH, Omizo MK, Silfen SL, Lombardi A. Skeletal consequences of hormone therapy discontinuance: a systematic review. Obstet Gynaecol Surv 2006;61:115-124.
37. Bagger YZ, Tanko LB, Alexandersen P, Hansen HB, Møllgaard A, Ravn P, Qvist P, Kanis JA, Christiansen C. Two to three years of hormone replacement treatment in healthy women have long-term preventive effects on bone mass and osteoporotic fractures: the PERF study. Bone 2004;34:728-736.
38. Lindsay R, Tohme JF. Estrogen treatment of patients with established postmenopausal osteoporosis. Obstet Gynecol 1990;76:290-295.
39. Abdalla HI, Hart DM, Lindsay R, Beastall GH. Organon OD 14 (tibolone) and menopausal dynamic hormone profiles. Maturitas 1986;8:81-85.
40. Rymer J, Robinson J, Fogelman I. Ten years of treatment with tibolone 2.5 mg daily: effects on bone loss in postmenopausal women. Climacteric 2002;5:390-398.
41. Horner E, Fleming J, Studd, JW. A study of women on long-term hormone replacement therapy and their attitude to suggested cessation. Climacteric 2006;9:459-463.
42. Rossouw JE, Prentice RL, Manson JE, Wu L, Barad D, Barnabei VM, Ko M, LaCroix AZ, Margolis KL, Stefanick ML. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. J Am Med Assoc 2007;297:1465-1477.
43. North American Menopause Society. Estrogen and progestogen use in peri- and postmenopausal women: March 2007 position statement of The North American Menopause Society. Menopause 2007;14:168-182.
44. Climacteric 2007 in press.
45. Genazzani AR, Gambacciani M, Simoncini T. The latest elaboration of the Women's Health Initiative data on hormone replacement therapy and cardiovascular disease in postmenopausal women. Gynecol Endocrinol 2007;23:183-185.